Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 8Recruiting 6Enrolling by invitation 2Active not recruiting 2Unknown 1Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Cancer Risk Syndrome 1Breast Neoplasms 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Genetic Counseling × Clear all
NCT04323774 2025-12-12

AYA-RISE

Dana-Farber Cancer Institute

Phase NA Active not recruiting
115 enrolled

Cancer Risk Syndrome

NCT05325151 2025-12-11

Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer

Ohio State University Comprehensive Cancer Center

Phase NA Active not recruiting
874 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡